For patients with phenylketonuria (PKU), \nyour decisions today could determine their tomorrow\n<\/h1>\n\t\t\t\t\t\t\t\t\t\t\t\t
PKU is characterized by a deficiency in phenylalanine hydroxylase (PAH) activity resulting in an excess of the amino acid phenylalanine (Phe) in the blood and brain. If not adequately controlled, Phe becomes neurotoxic and disrupts normal neurophysiology.1,2<\/sup><\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t\n
\n
This site has been developed for healthcare professionals who treat people with phenylketonuria (PKU). The site is meant to educate and heighten awareness of the PKU burden of illness, the impact of elevated phenylalanine (Phe), as well as the continued unmet need.1,2<\/sup><\/p>\n <\/div>\n\n